The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

By Mariam Sunny and Siddhi Mahatole (Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has ...

A single booster shot of MenQuadfi can be given to people ages 13 years or older who are at a continued risk of IMD if it’s been at least three years since their last meningococcal vaccine.

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as young as six weeks, expanding its previous label indicated for ...

The FDA has recently approved MenQuadfi, a meningococcal conjugate vaccine that protects against serogroups A, C, Y and W. The approval is for patients aged 2 years and older, according to a press ...

DUBLIN, June 15, 2020 /PRNewswire/ -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering.

The immunogenicity and safety of MenQuadfi were evaluated in over 6,300 healthy individuals aged 12 months and older, who received a single dose of MenQuadfi.1,2,3,4,5,6,7 MenQuadfi was compared ...

FDA to review MenQuadfi TM 1, a meningococcal vaccine candidate PARIS - June 27, 2019 - The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA ...

(RTTNews) - Sanofi said that the U.S. Food and Drug Administration has approved a Biologics License Application for MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive ...

European Commission approves MenQuadfi ®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older EC approval based on robust data from seven ...